Checks inherited gene changes in people with lung adenocarcinoma
Looks at inherited gene changes in Mexican patients with lung adenocarcinoma, a lung cancer.
Plain-language title generated from the registry record
Registry title: Pathogenic Variants in Genes Associated With Lung Adenocarcinoma
Key facts
- Where
- Mexico City, MexicoSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 16 and 85 years old?
Source: NCT06181812, who can take part
Where in Mexico
- Thoracic Oncology Unit and Personalized Medicine Laboratory, Instituto Nacional de CancerologíaMexico City, MexicoTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Oscar Gerardo Arrieta Rodríguez
- Trial code
- NCT06181812
- Record updated
- 8 April 2026
- Original description
The goal of this observational study is to describe the prevalence of germ line-pathogenic variants in Mexican patients with lung adenocarcinoma.Read full original descriptionShow less
Prevalence of Pathogenic or Likely Pathogenic Germline Variants in Cancer Predisposition Genes Among Patients With Lung Adenocarcinoma
The goal of this observational study is to describe the prevalence of germ line-pathogenic variants in Mexican patients with lung adenocarcinoma.
The main questions it aims to answer are:
1. What is the prevalence of pathogenic variants in genes associated with lung adenocarcinoma in Mexican patients younger than fifty? 2. Which clinical-pathological characteristics are associated with germ-line pathogenic variants in patients with lung adenocarcinoma? 3. How actionable somatic mutations are associated with germ line-pathogenic variants of patients with lung adenocarcinoma?
Participants will be asked to sign an informed consent; after that, they will be instructed to donate 10 ml of peripheral blood by venipuncture in the morning and before the patient has taken morning medication and the first meal, following a period of 8-12 hr fasting.
Inclusion: Both sexes; ≥ 16 years old, according the institutional protocols for new patients admittances; histologically confirmed lung adenocarcinoma (LUAD); Signed written informed consent form; A life expectancy greater than 8 weeks; Histologically confirmed LUAD and one of the following conditions: i) LCFH, defined as having one first-degree relative (FDR) or two or more second-degree relatives with LC, irrespective of the age at diagnosis. ii) Age at diagnosis ≤50 years, or ≤60 with a pack-years index. iii) Presence of ≥1 AGAs (EGFR, ALK, ROS1, KRAS, BRAF, MET exon 14 skipping, or RET).
Exclusion: A sample of peripheral blood that is not accessible; Insufficient clinical pathological information in the electronic clinical record; Elimination Criteria:; Withdrawal; Insufficient DNA quality and quantity for genomic sequencing analyses; Lost of follow up.